# High-dose Erythropoietin for Asphyxia and Encephalopathy

> **NCT02811263** · PHASE3 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 500 (actual)

## Conditions studied

- Neonatal Encephalopathy
- Birth Asphyxia

## Interventions

- **DRUG:** Normal saline placebo
- **DRUG:** Erythropoietin

## Key facts

- **NCT ID:** NCT02811263
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2021-10
- **Final completion:** 2022-04
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811263, "High-dose Erythropoietin for Asphyxia and Encephalopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02811263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*